<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736032</url>
  </required_header>
  <id_info>
    <org_study_id>12016</org_study_id>
    <nct_id>NCT02736032</nct_id>
  </id_info>
  <brief_title>Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist</brief_title>
  <official_title>Cryopreserved-thawed Embryo Transfer in Down or Non-down Regulated Hormonally Controlled Cycles: a Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nile Ivf Center, Cairo, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kamal Shaeer center of infertility</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally, the use of GnRH-a suppression was considered essential for adequate
      endometrial hormonal modulation in cryopreserved-thawed embryo transfer cycles. Several
      studies, however, have questioned its necessity for controlled endometrial preparation. Using
      a high dose of estradiol from day 1 of the cycle will suppress the gonadotroph, preventing
      folliculogenesis and excessive secretion of LH, allowing adequate endometrial preparation
      without GnRH-a.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5 weeks after embryo transfer]</time_frame>
    <description>the detection of intrauterine gestational sac with positive pulsations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>9 months</time_frame>
    <description>Pregnancy ending with a live birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estradiol and Progesterone levels on day of start of progesterone supplementation</measure>
    <time_frame>12 to 20 days</time_frame>
    <description>The serum levels of estradiol and progesterone before embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness on day of start of progesterone supplementation</measure>
    <time_frame>12 to 20 days</time_frame>
    <description>The endometrial thickness on the day of starting progesterone supplementation to transfer the embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days needed for adequate (&gt; 8mm) endometrial thickness</measure>
    <time_frame>12 to 20 days</time_frame>
    <description>Number of days on external hormones to prepare endometrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle cancellation: not related to thawing, thin endometrium, high P. OR related to embryos not surviving thawing.</measure>
    <time_frame>12 to 20 days</time_frame>
    <description>Cycle cancellation: not related to thawing, thin endometrium, high Progesterone. OR related to embryos not surviving thawing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>positive serum Beta HCG 14 days after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate.</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>the ratio between the number of embryos transferred and the number of sacs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy loss in the first 12 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy ongoing beyond 12 weeks gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>With GnRHa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without GnRHa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embryo transfer</intervention_name>
    <description>The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy</description>
    <arm_group_label>With GnRHa</arm_group_label>
    <arm_group_label>Without GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serum Estradiol and Progesterone levels</intervention_name>
    <description>Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation</description>
    <arm_group_label>With GnRHa</arm_group_label>
    <arm_group_label>Without GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>GnRH agonist given on day 21 of the cycle preceding the embryo transfer</description>
    <arm_group_label>With GnRHa</arm_group_label>
    <other_name>Decapeptyl SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>External Estradiol</intervention_name>
    <description>Estradiol started on day1 of the cycle for endometrial prepartaion</description>
    <arm_group_label>With GnRHa</arm_group_label>
    <arm_group_label>Without GnRHa</arm_group_label>
    <other_name>estradiol valerate of Cycloprogenova tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>progesterone as luteal phase support start after endometrium is well prepared</description>
    <arm_group_label>With GnRHa</arm_group_label>
    <arm_group_label>Without GnRHa</arm_group_label>
    <other_name>Cyclogest vaginal suppositories</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-35 years

          -  BMI 20-30

          -  Regular menses.

          -  No PCOS, no endometriosis

          -  No uterine anomalies or lesions

          -  No severe male factor

          -  All grade 1 cleaved stage embryos

        Exclusion Criteria:

          -  Less than 20 or more than 35 years

          -  BMI less than 20 or more than 30

          -  Irregular cycles

          -  PCOS or endometriosis

          -  Uterine anomalies or lesions

          -  Severe male factor

          -  Poor quality embryos for transfer

          -  Severe
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eman K Shaeer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)</name>
      <address>
        <city>Cairo</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamal Shaeer center of infertility</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nile IVF center</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>May 12, 2018</last_update_submitted>
  <last_update_submitted_qc>May 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Yasmin Ahmed Bassiouny</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

